LM-061 + toripalimab

LM-061 + toripalimab is an investigational **drug combination** being studied in a phase I trial for advanced tumors. **LM-061** is a compound whose precise mechanism is not publicly defined, but is being investigated in oncology settings. **Toripalimab** is a recombinant, humanized monoclonal antibody against **programmed death protein 1 (PD-1)**, functioning as a **checkpoint inhibitor** that blocks PD-1 to enhance T cell-mediated anti-tumor immune responses. Toripalimab has received approvals for conditions like melanoma and nasopharyngeal carcinoma, and is often combined with other agents in clinical research[1][2][7]. The mechanism for LM-061 is not described in current clinical or regulatory public sources. The drug combination involves fixed dose injections of both agents every 3 weeks in a phase I dose-escalation and combination study for subjects with advanced tumors[7].

Other names

LM-061 + toripalimabLM-061 and toripalimabLM061 and toripalimabLM 061 and toripalimab